TKL Research Agrees to Sell Clinical Trials Division
TKL Research, a dermatology specialty clinical research organization , announced that it has signed an agreement to sell its Clinical Trials Division to QuintilesIMS....
Novartis Buys U.S. Sickle Cell Drugmaker Selexys
Novartis is buying U.S.based Selexys Pharmaceuticals in a deal worth up to $665 million, the Swiss drugmaker said on Monday, expanding its pipeline of...
Amgen Announces 2016 Third Quarter Dividend
Amgen announced that its Board of Directors declared a $1.00 per share dividend for the third quarter of 2016. ...
Gilead Sciences to Release Second Quarter 2016 Financial Results
Gilead Sciences, Inc announced that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes. At 4:30...
Alexion Pharmaceuticals to Report Second Quarter 2016 Results
Alexion Pharmaceuticals Inc announced that the Company will report its financial results for the second quarter ended June 30, 2016 on Thursday, July 28,...
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm,...
Sanofi Announces Expiration Of HSR Waiting Period Regarding Proposed Acquisition Of Medivation
Sanofi announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connection with Sanofi’s intent to acquire...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...